Leap Therapeutics, Inc. (NASDAQ:LPTX) missed earnings with its latest quarterly results, disappointing overly-optimistic forecasters. It was not a great statutory result, with revenues coming in 87% lower than the analysts predicted. Unsurprisingly, earnings also fell seriously short of forecasts, turning into a per-share loss of US$0.55. This is an important time for investors, as they can track a company’s performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
After the latest results, the three analysts